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Introduction: Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, and there 
are currently no disease-modifying therapies available. Inflammation and network dysfunction 
precede the development of Alzheimer pathology and are thought to contribute to the 
development of pathology. Early intervention at this preliminary stage has the potential to modify 
the course of the disease. Cannabidiol (CBD) has both anti-inflammatory and network stabilizing 
effects which may be mediated through cannabinoid-like receptors such as GPR55. Our 
objective was to determine if CBD has neuroprotective properties in an in vitro model of 
Alzheimer’s disease pathogenesis and to identify the receptors through which CBD mediates its 
effects. Methods: To better understand the potential neuroprotective properties of CBD in early 
AD pathology, we evaluated calcium signaling and regulation of intracellular calcium in CBD-
treated neurons challenged with an inflammatory stimulus. We also investigated the role of CBD 
as an anti-inflammatory agent by pretreating microglia with CBD before exposure to Aβo and 
then measuring the effects of the conditioned medium on neurons. We measured network 
stabilizing properties using microelectrode arrays to record the activity of neurons treated with 
CBD and challenged with an inflammatory stimulus. To investigate which receptors mediate the 
effects of CBD, we treated neurons and macrophages with cannabinoid ligands and measured 
the effect on calcium signaling. Results: CBD treatment of neurons offered partial protection 
against Aβ-induced inflammatory damage while CBD treatment of microglia conferred greater 
protection. In neurons, CBD increased and synchronized neuronal calcium signaling and 
network activity. The agonist stimulation profiles suggested that the neuroprotective effects of 
CBD may be induced by modulating GPR55 receptors. CBD induced an increased number of 
shorter electrophysiological bursts in neuronal network activity on the MEA indicating control 
over bursting activity that may contribute to protection. Network analysis of the effects of CBD 
indicated that it stabilized the neurons by suppressing hyperactivity.  When microglia were 
treated with CBD, the release of toxins from microglia was inhibited, indicating that an “anti-
inflammatory” effect may confer neuroprotection than could exceed the effects on neurons.  
Cannabinoid ligands each induced unique calcium signaling profiles on macrophages with CBD 
and NAGly inducing similar effects on calcium spike frequency suggesting modulation of the 
GPR18 receptor on macrophages. In addition, LPI induced strong and persistent activation of 
the macrophages, whereas 2-AG suppressed signaling indicating complex cannabinoid control 
of these cells.  Conclusions: Our findings support the hypothesis that CBD has neuroprotective 
potential for AD patients through the suppression of inflammation and regulation of network 
activity.  The mechanisms of CBD action are not well understood, but the findings indicate that 
actions at GPR55, GPR18, and other receptors are candidates for novel therapies that suppress 
pathogenesis in the early stages of Alzheimer’s disease.  
Introduction 
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, currently 
affecting 5.4 million Americans and estimated to increase to 13.8 million Americans by 2050 
(Gaugler et al. 2016). Current treatments for AD provide limited alleviation of cognitive decline in 
early stages of the disease, are ineffective against disease progression, and are designed to 
manage symptoms without targeting the underlying neuropathology (Karl et al. 2012; Briggs et 
al. 2017). Thus, new treatment strategies are needed for the growing multitude of patients 
suffering from this disease. 
Disease-modifying treatments will likely be most effective during the early stages of AD 
where the pathogenic process can be modified.  Early targets for intervention include both 
inflammation and a hyperexcitable state that are thought to contribute to disease progression. 
Inflammatory activity destabilizes calcium regulation in neurons, which promotes cytoskeletal 
damage, loss of transport and focal accumulation of proteins and organelles that set the stage 
for synaptic dysfunction, hyperexcitability, and pathogenesis (Born 2015; Cook et al. 2015; 
Horváth et al. 2016; Nicastro et al. 2016). The functional impact of inflammation includes 
enhanced neural sensitivity. Basic and clinical studies support the presence of hyperexcitable 
phenotypes in AD demonstrated as an increased prevalence of both clinical and subclinical 
seizures (Born 2015; Cook et al. 2015; Horváth et al. 2016; Nicastro et al. 2016).   
Observations in AD patients are similar in many respects to studies in epilepsy (Ravizza 
et al. 2011; Galic et al. 2012; Devinsky et al. 2013; Auvin et al. 2015; Vezzani 2015), where the 
link between inflammation and neural activity is well developed.  Efforts to control this activity 
have shown that inflammation and seizures are reduced by CBD (Devinsky et al. 2018b, a; 
Thiele et al. 2018) and CBD has been approved for treatment of patients with uncontrolled 
seizure activity 
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000Approv.pdf).  
Since hyperactive neuronal activity is linked to cognitive dysfunction, interventions that 
normalize network activity have the potential to reduce cognitive deficits. Thus, the unique ability 
of CBD to reduce inflammation and stabilize network activity (Iuvone et al. 2009; Scuderi et al. 
2009) offers promise to slow AD pathogenesis (Aso and Ferrer 2016).  
In spite of the clinical successes with CBD, it is unclear which receptors mediate the 
beneficial effects of CBD. CBD has a low affinity for both cannabinoid receptor types 1 and 2 
(CB1 and CB2, IC50 ~3 and 30 µM, respectively).  In addition, the role of various target cells is 
unclear.  CB1 is primarily located in the CNS with a higher prevalence on GABAergic 
interneurons versus excitatory neurons (Busquets-Garcia et al. 2018), and CB2 is located 
primarily on cells of the immune system (Turcotte et al. 2016a) including brain microglia.  Some 
studies report CBD acting as an antagonist of CB1 and a reverse agonist of CB2 (Pertwee 2008; 
Ibeas Bih et al. 2015). In microglia, CBD acts as a CB2 inverse agonist which inhibits cell 
migration and may contribute to its anti-inflammatory properties (Kim et al. 2008; Pertwee 
2008).  The low affinity of CBD has raised questions regarding the role of CB1 and CB2 as 
circulating concentrations in vivo, in the mid to high nanomolar range (Taylor et al. 2018; Millar 
et al. 2018), would provide relatively low receptor occupancy.    
In addition to CB1 and CB2, GPR55 may be target for CBD, as growing evidence 
suggests that GPR55 may mediate the anti-inflammatory effects (Anavi-Goffer et al. 2012; 
Kallendrusch et al. 2013; Mellini et al. 2014; Chiurchiù et al. 2015; Turcotte et al. 2016b). 
GRR55 is a non-endocannabinoid G protein-coupled receptor that shares similarities in 
structure to cannabinoid receptors (Pertwee 2008). CBD has been shown to have a much 
higher affinity (445 nM) for GPR55 and antagonistic effects have been reported, which would be 
consistent with the antiepileptic effects of CBD based on the role of GPR55 in modulating 
synaptic transmission (Pertwee 2008). GPR18 is another non-cannabinoid receptor which is 
inhibited by CBD although the affinity for GPR18 is relatively low (51 µM) (McHugh 2012).  
However, much less is known about the potential role of GPR55 or GRP18.   
This research was designed to determine whether CBD has neuroprotective effects in an 
in vitro model of early AD pathogenesis and to identify which receptors and actions might 
modulate the effects. More specifically, we investigated whether CBD protects from neuronal 
damage due to AD-like inflammatory changes and if these neuroprotective effects were 
mediated through direct effects on neurons or via anti-inflammatory effects at microglia. 
Additionally, we investigated the ability of CBD to stabilize neuronal networks and the possible 
role of GPR55 receptors.  
 
Methods  
Neuronal Cultures  
Neurons were cultured in Neurobasal medium + B27 based on published protocols 
(Meeker et al. 2016). To collect neurons, a pregnant (E16) female mouse was euthanized in 
isoflurane and the fetuses placed in ice cold Hank’s balance salt solution. After transecting the 
brainstem, the brain was removed, and the cortex and hippocampus were collected and placed 
in papain at 10 U/ml with 2.5 U/ml DNase.  To produce a single cell suspension, tissue was 
gently triturated and then diluted in Neurobasal Plus+B27 Plus+5% FBS+glutamine+20 µg/ml 
gentamicin.  Cells were seeded onto poly-D-lysine coated coverslips at 10,000-20,000 cells/cm2 
for calcium imaging studies.  For MEA studies, the electrode grid was coated with 0.005% 
polyethyeneimine (PEI) and laminin (10 µg/ml) and the dissociated neurons were seeded at 
50,000 cells/cm2. Once seeded and attached, the almost pure (>95%) neuronal cultures were 
fed with Neurobasal Plus+B27 Plus+0.5 mM glutamine three times a week.  
 
Microglial cultures 
Microglial cultures were initiated as micro explants of E16 fetal brain grown in 
suspension culture on ultra low adhesion plastic. Microglia were fed three times a week with 
DMEM-H+10%FBS+20 µg/ml gentamicin. Microglia initially grow within the explants but as they 
mature over ~2 weeks they migrate from explants and are the only cells that adhere to the low 
adhesion plastic. After ~3 weeks, a monolayer of highly purified microglia was established on 
the plastic.  Cells in suspension were washed from the well prior to use leaving a pure layer of 
microglia.  Human monocyte derived macrophages were grown from isolated peripheral blood 
mononuclear cells in complete DMEM according to standard protocols.   
Microglial conditioned medium 
 To recapitulate pathological conditions associated with inflammation, primary cultured 
neurons were treated with microglial conditioned medium (MGCM), which was produced by 
exposing microglia to Aβ oligomers (Aβo) freshly prepared from a 1 μM stock of monomeric Aβ 
stock. Microglia were washed and treated in serum free, phenol red free DMEM (2 mls/60 mm 
dish) for 1 hour. This medium was then replaced with medium containing Aβo and the microglia 
were incubated for 1 hour to produce MGCM from the activated microglia. The medium was 
then collected and centrifuged at 1000 x g to remove any particulate material and the 
supernatant was ultrafiltered at 300 kDa MWCO.  
Exposure to Aβo triggered the secretion of factors that are toxic to neurons.  MGCM was 
delivered at dilution of 1:5 for live cell calcium imaging and electrophysiological recording 
(MEAs). The response of neurons to these factors in vitro was similar to that evoked in vivo 
using mouse models of AD(Kuchibhotla et al. 2008; Bittner et al. 2010).  
 
 
Live cell calcium imaging  
Since the actions of cannabinoid ligands and inflammatory stimuli often signal via 
increases in intracellular calcium, we used live cell calcium imaging to monitor changes in 
cellular neuronal calcium over time.  In addition, dysregulation of calcium in neurons is believed 
to be an initial step contributing to neurodegenerative pathologies (Bragg et al. 2002; Meeker et 
al. 2005, 2012, 2016; Meeker 2007) thereby providing insight into the potential role of 
cannabinoid signaling in early pathogenesis.  Neurons or macrophages cultured on poly-D-
lysine coated coverslips were loaded with 1µM Fluo-4 and transferred to a specialized 
microscopic chamber for imaging at a final magnification of 674X.  MetaMorph Image Analysis 
Software was used to capture time lapse images for both acute (every 6 sec for 6 min) and 
delayed (every min for 40 min) calcium changes.  For the analysis, each neuron cell in the field 
was traced and the fluorescence was recorded at baseline and post challenge.  The frequency 
and height of small intrinsic calcium spikes were quantified for each neuron as well as the acute 
peak and extent of delayed calcium accumulation.  
Microelectrode arrays 
 Optically transparent 60 electrode microelectrode arrays (MEAs) coated with 0.005% 
polyethyleneimine (PEI) were seeded with neurons at a concentration of 50,000 cells/cm2. The 
MEAs were used to record network wide electrophysiological bursts of neural activity which 
provided measures of network connectivity and communication efficiency.  Studies have 
suggested that network dysfunction may appear early in AD in the form of hyperactivity and 
subclinical seizures (Born 2015; Cook et al. 2015; Horváth et al. 2016; Nicastro et al. 2016) yet 
little work has been done to characterize the changes in network function and the effects of 
cannabinoids that may afford protection.  We therefore assessed the effects of various 
cannabinoid ligands on network hyperexcitability, neural network synchronization, and network 
connectivity to evaluate effects of various cannabinoid ligands.   
Statistical analyses 
Prism 5 software was used to perform analysis of variance with planned multiple 
comparisons and paired and unpaired t tests, depending on the design of the experiment. 
Statistical significance was determined using Holm-Sidak and Tukey corrections for multiple 
comparisons with alpha=0.05. 
Cannabinoid ligands used to examine the pharmacology of CBD actions 
As CBD displays high affinity for GPR55 and low affinity for CB1 and CB2, we 
hypothesized that the beneficial effects of CBD at typical plasma concentrations were likely to 
be due to interactions between CBD and GPR55 and/or GPR18. To test this hypothesis, we 
treated both neurons and macrophages with the ligands outlined in Table 1. 
Table 1. Cannabinoid ligands. Cannabinoid agonists and antagonists used to stimulate either neurons 
or macrophages in live cell calcium imaging experiments. aConcentration based on estimates of 






CBD treatment of neurons offers partial protection against Aβ-induced inflammatory 
damage  
Previous studies have indicated that the beneficial actions of CBD could be due to either 
direct stabilization of neural activity or via anti-inflammatory effects on microglia.  To test the 
effect of CBD on neurons under conditions that recapitulate features of early AD pathogenesis 
(Kuchibhotla et al. 2008; Bittner et al. 2010), we treated primary mouse microglia with Aβo and 
collected the conditioned medium (microglial conditioned medium; MGCM).  After a 10 minute  
baseline period with either CBD or vehicle, MGCM was applied to neurons (1:5 dilution in aCSF) 
to recapitulate “inflammatory” conditions associated with early AD pathology.  
Figure 1.  CBD treatment of neurons challenged with MGCM enhanced acute calcium 
responses and suppressed long term calcium accumulation. A. Time lapse images of neuronal 
calcium signaling. Baseline calcium at 0 minutes shows the neurons prior to MGCM challenge. 
Immediately after the MGCM challenge at 0.1 minutes neuronal calcium increases followed by 
partial recovery at 0.5 minutes and then a chronic accumulation of calcium at 27 minutes. B. Time 
lapse changes in intracellular calcium illustrating the acute peak and delayed destabilization. C. 
Average calcium levels achieved in the acute peak (0-3 minutes, p<0.001, N=4 experiments), and 
delayed calcium rise (22-30 minutes, p<0.001, N=4 experiments). D. Neurons not treated with CBD 
experienced a decrease in the frequency of individual neuronal calcium signaling events from 
baseline once challenged with MGCM. Neurons treated with CBD retained a significantly greater 
frequency in calcium signaling after the MGCM challenge (p=0.032, N=4 experiments)  
Figure 1A shows images of neurons loaded with the calcium-sensitive dye Fluo-4 before 
applying MGCM (0 minutes) and immediately after treatment with MGCM (0.1 minutes) 
illustrating the acute rise in intracellular calcium. The acute calcium response recovers 
substantially but remains higher than baseline intracellular calcium (0.5 minutes). After 27 
minutes with the MGCM challenge, a delayed increase in intracellular calcium was seen that 
failed to recover and was accompanied by beading of dendritic processes. Figure 1B illustrates 
the average temporal changes in neuronal intracellular calcium when neurons were pretreated 
with CBD and then challenged with MGCM at 0 minutes. No significant effects of CBD on 
calcium accumulation were seen during the 10-minute pre-challenge baseline.  After the MGCM 
challenge, CBD significantly enhanced the acute calcium response and suppressed long term 
calcium accumulation. The average changes in intracellular calcium are summarized in Figure 
1C, for the acute peak (0-3 minutes) and the delayed calcium rise (22-30 minutes).  Since the 
delayed accumulation of calcium is correlated with neural damage, the modest 33% 
suppression by CBD treatment of the neurons indicated partial protection due to stabilization of 
the neuronal calcium homeostasis in response to the inflammatory challenge.     
In addition to intracellular calcium accumulation, we looked at the effect of CBD on 
individual neuronal calcium signaling events (not shown, but see below) after challenging 
neurons with MGCM. These small calcium spikes reflect intrinsic signaling events in single cells 
that are masked in the averaged data. Figure 1D illustrates that CBD had no effect on normal 
signaling but partially prevented the loss of calcium signaling after the MGCM challenge.   
CBD synchronized neuronal calcium signaling and network activity 
As CBD showed a direct effect on the neurons in our experiments, we treated neurons 
directly with both CBD and cannabinoid agonists to determine which receptors CBD may be 
acting on to modulate calcium signaling of neurons.  We compared the effects of CBD and each 
agonist to their pre-treatment baseline and to vehicle-treated neurons.  Figures 2B-E 
demonstrate the variable changes seen in neuronal calcium signaling during treatment with 
cannabinoid receptor agonists as compared to baseline (vehicle) activity (Figure 2A). CBD 
Figure 2. CBD increased average intensity of neuronal calcium signaling and promoted 
synchronization. A-E. Composite profiles of calcium spikes in murine neurons illustrate increased 
synchronization of spikes induced by CBD. F. Average of all runs show that CBD and LPI induced 
increased synchronization of neurons. G.  CBD and 2-AG induced an increased average calcium 
spike rate as compared to pre-treatment. H. CBD induced increased average calcium spike height 
relative to pre-treatment. * = p<0.05, analysis of variance with post-hoc multiple comparisons  
induced calcium spikes of high intensity (note scale change in Figure 2B) as compared to 
vehicle. Notably, the pattern of spikes induced by CBD was characterized by a high degree of 
synchrony, illustrated in Figure 2B by the superimposed peaks throughout the run. LPI induced 
smaller calcium spikes but also showed a tendency toward synchronous activity (Figure 2E).  2-
AG increased the frequency of calcium spikes relative to pre-treatment (Figure 2C) but did not 
show synchronized activity. Treatment with NAGly had no effect on calcium signaling. 
Quantification of the extent of synchronous activity under the various conditions in Figure 2F 
illustrates the significantly higher proportion of synchronized calcium spikes in the presence of 
CBD and LPI.  Average spike rates were significantly increased for CBD and 2-AG but not LPI 
(Figure 2G), whereas an increased intensity of the calcium response was only seen with CBD 
(Figure 2H).  Thus, CBD has complex properties that overlap with several different cannabinoid 
agonists.    
Since CBD has been shown to stabilize epileptiform activity and, in our experiments, 
synchronize calcium signaling of neurons, we investigated the changes in neural network 
communication induced by CBD. We used 60 channel microelectrode arrays (MEAs) to record 
network-wide electrophysiological bursts of neural activity and measured network connectivity 
and communication efficiency of neurons. Figure 3A shows the MEA seeded with neurons, and 
Figure 3B shows examples of the recording on a subset of electrodes in the absence or 
presence of CBD. Each rectangle in Figure 3B corresponds to a single electrode. These 
recordings were converted to raster plots, shown in Figures 3C-D which show the activity of 
each electrode (Y axis) over time (X axis).  We recorded the electrophysiological activity of 
neurons at baseline for 10 minutes, then added CBD and recorded for an additional 10 minutes. 
The raster plots illustrate the synchronous bursts of activity which appear as a vertical line.  
Treatment with CBD shifted the pattern toward an increased number of bursts with a regular 
bursting pattern (Figure 3D) as compared to vehicle (Figure 3C).  Quantification of the 
properties of the burst over the entire 10 minute run for three independent MEAs showed that 
CBD did not change the frequency of spiking in each burst as compared to control (Figure 3E), 
Figure 3. CBD induced a greater number of shorter bursts in neuronal 
electrophysiology as compared to control.  A. A 60 electrode microelectrode array 
seeded with neurons at a concentration of 50,000 cells/cm2. B. Illustration of extracellular 
recordings from murine neurons in the absence or presence of CBD showing the spikes that 
occur in each burst. A subset of the 60 channels is shown.  C. Spike raster plot for control 
neurons. D. Spike raster plot for neurons treated with CBD shows increased and regular 
bursting pattern induced by CBD.  E. CBD did not change the frequency of spiking in each 
burst as compared to control. F. CBD increased the number of bursts as compared to control. 
G. CBD decreased the duration of each burst as compared to control. * = p<0.05, analysis of 
variance with post-hoc multiple comparisons  
while the number of bursts increased significantly (Figure 3F) and the length of the bursts was 
shorter (Figure 3G).  To examine the translation of these effects to the inflammatory setting, 
neurons on the MEA were challenged with MGCM in the presence or absence of 1 µM CBD.  
Analysis of the network activity, summarized in Figure 4, showed that the hyperactive response 
to the MGCM was significantly diminished in the presence of CBD.   Both treated and non-
treated MEAs had a subset of cells that deceased firing in response to the MGCM.  CBD also 
had a small normalization effect on these cells, bringing them back toward baseline 
characteristics.  Thus, CBD appeared to modulate the activity of the neurons in a fashion that 
retains normal firing and network activity.  
CBD treatment of microglia offers greater protection against Aβ-induced inflammatory 
damage 
As anti-inflammatory effects of CBD could also contribute to its beneficial effects, we 
treated microglia with CBD to determine if it could reduce the level of neurotoxic activity.  We 
measured the calcium signaling and accumulation in neurons challenged with MGCM collected 
from microglia treated with CBD prior to exposure to Aβo. Figure 5A illustrates the temporal 
Figure 4.  CBD normalized and stabilized neuronal networks during an inflammatory 
challenge.  A network analysis of the percent change in firing rates of neurons on the MEA 
after challenging with MGCM showed that CBD significantly decreased the hyperactive 
response.  In addition, a sub-analysis of the neurons showed that fewer cells lost activity in the 
presence of CBD. 
changes in neuronal intracellular calcium following a challenge with MGCM at 0 minutes. The 
accumulation of neuronal calcium in response to MGCM from the CBD-treated microglia was 
greatly reduced in both the acute (0-6 minutes) and delayed (6-46 minutes) phases relative to 
vehicle treated microglia (Figure 5B).  CBD resulted in a 48% reduction in delayed calcium 
accumulation as compared to the 33% reduction when the neurons were pretreated with CBD, 
indicating that the ability to suppress the release of neurotoxic factors may be of equal or 
greater importance than the effects directly on neurons.   
Cannabinoid agonists induce unique calcium signaling profiles in macrophages.   
Since the MGCM studies showed that CBD has an effect on mouse microglia, we 
treated human monocyte-derived macrophages with the same cannabinoid ligands used for the 
analysis of neuronal activity.  The effects of the cannabinoid ligands on macrophages 
contrasted significantly with the effects on neurons. Figure 6 demonstrates the variable changes 
in macrophage calcium signaling in response to treatment with cannabinoid receptor agonists 
as compared to baseline (vehicle) activity (shown in Figure 6A). CBD induced an acute increase 
in calcium spikes in macrophages that recovered after approximately 12 minutes (Figure 6B). 
Figure 5. Anti-inflammatory effects of CBD on neuronal calcium accumulation. CBD 
treatment of microglia decreases secretion of neurotoxic factors based on suppression of 
delayed calcium accumulation. A. Time lapse changes in neuronal intracellular calcium 
demonstrate that CBD suppressed calcium accumulation. B. CBD decreased peak calcium 
levels achieved in acute (0-6 minutes, p<0.001, N=5 experiments) and delayed (6-46 minutes, 
p<0.001, N=5 experiments) phases. 
 
NAGly treatment largely recapitulated the effect of CBD, with an acute increase which 
recovered with a similar time course (Figure 6C).  2-AG induced a brief calcium spike which was 
Figure 6. Agonists targeting different cannabinoid receptors produce distinctively 
different calcium signaling in primary human monocyte-derived macrophages. 
Composite profiles of calcium spikes in cultured macrophages illustrate baseline activity 
(vehicle), acute increases in calcium signaling frequency induced by CBD and LPI, a 
more acute increase with NAGly and a decrease with 2-AG indicating substantial 
diversity in the regulation of macrophage activity by the cannabinoid ligands. F. CBD and 
LPI yielded the greatest mean increase in spike frequency. G. NAGly, CBD, and 2-AG 
increased intensity of the calcium spikes. * = p<0.05, analysis of variance with post-hoc 
multiple comparisons 
F G 
rapidly followed by suppression of calcium signaling activity in the macrophages (Figure 6D). 
LPI induced a modest acute spike followed by sustained activity in the macrophages (Figure 
6E). Figure 6F displays the calcium spike frequency of macrophages before and after treatment 
with the agonists, showing that CBD and LPI yielded the greatest mean increase relative to pre-
treatment.  The average intensity of calcium spikes is summarized in Figure 6G.  NAGly, CBD, 
and 2-AG all increased calcium spike intensity in macrophages as compared to vehicle. Thus, 
CBD may be acting through both GPR18 and GPR55 receptors on macrophages to affect 
calcium signaling and inflammatory activity.  
The response of macrophages showed some similarities to neurons but also dramatic 
differences.  CBD increased the calcium spike rate and the peak intensity in both neurons and 
macrophages.  However, LPI and NAGly did not change the calcium spike rate in neurons but 
increased the calcium spike rate in macrophages. 2-AG and NAGly did not change the calcium 
peak height in neurons but increased calcium peak height in macrophages. Thus, CBD and the 
cannabinoid agonists have unique effects on neurons and macrophages. While our data 
supports CBD actions at GPR55 on neurons, it appears that CBD may be acting through both 
GPR18 and GPR55 receptors on macrophages. 
 
Discussion 
Inflammation appears early in neurodegenerative diseases and may enhance the 
vulnerability of neurons to disease progression.  Therapeutic intervention at this early stage will 
likely have the greatest impact, as the pathology is not well developed and may still be 
reversible.  Successful intervention therefore could have disease modifying potential.  Our study 
found that CBD has complex actions that could offer protection against Aβ-induced 
inflammatory damage through actions at both neurons and microglia.  
Neuroprotective potential of CBD 
CBD treatment of neurons caused a modest stabilization of neuronal calcium 
accumulation in response to an inflammatory challenge indicating suppression of pathogenesis. 
This suppression of calcium accumulation demonstrates the ability of CBD to stabilize neuronal 
calcium regulation in response to an inflammatory challenge. In our model of early AD 
pathogenesis, the acute intracellular calcium accumulation that follows a challenge with MGCM 
quickly recovers. The delayed calcium accumulation that slowly increases over time is more 
toxic to the neurons, as these cells generally do not recover from the chronic increase in 
intracellular calcium. This delayed calcium dysregulation increases the neuronal vulnerability to 
further AD pathogenesis. The in vitro calcium dysregulation closely mimics in vivo 
destabilization of neuronal calcium in mouse models of AD where chronically elevated calcium 
is seen in neurons near amyloid plaques and activated microglia (Kuchibhotla et al. 2008; 
Bittner et al. 2010).  The dysregulation leads to cytoskeletal damage, posttranslational 
modifications of tau protein, neuronal death and synapse loss. The ability of CBD to suppress 
calcium accumulation could protect neurons by inhibiting the development of this pathology. In 
this way, direct stimulation of neurons with CBD may be neuroprotective in the setting of early 
AD pathology. How CBD induces these beneficial effects is not clear but some clues have 
emerged from the examination of the effects of agonists targeting the receptors, CB1/CB2, 
GPR55 and GPR18.  CBD had unique effects on neuronal calcium signaling, inducing strong 
calcium spikes that were highly synchronized between neurons.  The GPR55 agonist, LPI, 
increased the synchronization of calcium activity but the magnitude of signaling was relatively 
weak. The mixed agonist, 2-AG, increased the intensity of the calcium spikes but not the 
synchronization.  Together these effects suggest that CBD may be acting through GPR55 
receptors on neurons but may also have additional targets.  GPR18 does not appear to play a 
role in regulating neural activity. 
CBD promoted increased efficiency of neuronal network communication   
The increased synchronization of calcium spikes suggested increased efficiency of calcium 
signaling. Analysis of action potential firing and network electrophysiological activity on the 
MEAs showed that CBD induced a greater number of shorter bursts. This suggests that CBD 
restricts the generation of long bursts of action potentials.  Neurons recovered more quickly 
after each electrophysiological burst of neural activity, allowing the generation of short, highly 
synchronized bursts of activity that may allow for more efficient network communication.  
Destabilized, hyperactive network activity may be a treatable cause of cognitive dysfunction in 
AD.  Hyperactive network behavior may be responsible for the increased subclinical epileptiform 
activity seen in AD (Born 2015; Cook et al. 2015; Horváth et al. 2016; Nicastro et al. 2016). CBD 
has well established network stabilizing effects in patients with seizures and these properties 
may reduce hyperactivity and prove beneficial in AD.  The ability of CBD to normalize network 
activity in the presence of an inflammatory stimulus (MGCM) indicated that it somehow prevents 
the development of aberrant activity under inflammatory conditions.  Overall, these findings 
indicate that CBD may help to keep neural activity in check by regulating the properties of 
network bursts, in part, due to stabilization of calcium homeostasis.   
CBD suppressed inflammation  
While beneficial effects of CBD were seen on neurons, the ability to suppress the 
release of neurotoxic factors from activated microglia may provide “anti-inflammatory” effects 
that confer even greater neuroprotection. In our model, microglia were exposed to Aβo, which 
triggered the secretion of pro-inflammatory soluble factors and cytokines, mimicking early 
events associated with the development of AD. In neurons, these microglial products induce a 
dysregulation of intracellular calcium (Guo et al. 1999; Abramov et al. 2004; Kuchibhotla et al. 
2008; Bittner et al. 2010; Um et al. 2013), as well as sensitization of NMDA glutamate receptors 
(Xiong et al. 2004; Floden 2005; Ittner et al. 2010; Roberson et al. 2011; Paula-Lima et al. 2013; 
Molokanova et al. 2014; Ferreira et al. 2015; Hamilton et al. 2015), mislocalization/accumulation 
of Tau in dendrites (Ittner et al. 2010), focal swellings,(Yoshiyama et al. 2007; Kuchibhotla et al. 
2008), loss of cytoskeletal structure and impaired transport (Yoshiyama et al. 2007; Meeker et 
al. 2016). These changes are analogous to those seen in early AD pathogenesis.  The 
decreased ability of the conditioned medium to induce calcium dysregulation after exposure to 
CBD demonstrated an “anti-inflammatory” effect which may restrict the ability of Aβo to generate 
a toxic inflammatory response. Suppression of the release of neurotoxic factors from microglia 
by CBD could therefore modify disease progression in the early stages of AD pathogenesis. 
Previous studies have suggested that CBD could have anti-inflammatory effects through a 
variety of mechanisms, such as the ability to inhibit the migration of immune cells and the 
activation of microglia (Karl et al. 2012). Our data confirmed beneficial actions of CBD at 
microglia, but showed an effect that would be independent of migration. The anti-inflammatory 
properties demonstrated through our studies highlight the ability of CBD to decrease the 
neurotoxicity of the microglial secretome in early AD pathogenesis.  As inflammation may 
represent an early event that alters the function of neuronal networks and contributes to 
cognitive decline, these findings underscore the impact of the inflammatory system in the early 
pathology of AD and the possible benefit to be realized with CBD through its anti-inflammatory 
properties.  
CBD induced increased calcium signaling of macrophages 
As seen in the neurons, cannabinoid ligands each induced unique calcium signaling 
profiles on macrophages.  However, the actions were distinctively different in the two cell types.  
Notably, NAGly-induced calcium signaling in macrophages largely recapitulated the effect of 
CBD, suggesting that CBD may be acting through GPR18 receptors on macrophages to 
increase calcium signaling. Macrophages express both GPR18 and GPR55 receptors and both 
may have a role in the regulation of macrophage functions.  LPI also induced strong calcium 
signaling but was characterized by a continuous activation.  In contrast, 2-AG potently 
suppressed activity after a very brief calcium spike.  Although both 2-AG and LPI are agonists of 
GPR55, it is noteworthy that they induced opposite effects on calcium signaling in 
macrophages. This suggests that effects of 2-AG at CB1 and CB2 may contribute to the 
regulation of calcium signaling in macrophages.  These data indicate that CBD has actions on 
macrophages consistent with activation of GPR18 but that GPR55 and CB1/CB2 receptors also 
can exert significant effects on calcium signaling that may play a role in the regulation of 
inflammatory activity.  
Conclusion  
CBD treatment of neurons caused a modest stabilization of neuronal calcium 
accumulation in response to an inflammatory challenge indicating suppression of pathogenesis. 
CBD had a larger effect on the release of toxins from microglia indicating that the “anti-
inflammatory” effects may confer greater neuroprotection. CBD promoted greater 
synchronization of neuronal calcium signaling and a greater number of shorter bursts on the 
MEA suggesting more efficient network communication and decreased network excitability 
which may contribute to protection.  These effects may be modulated by GPR55 on neurons. 
Cannabinoid ligands each induced unique calcium signaling profiles on macrophages with CBD 
and NAGly inducing similar effects, suggesting that CBD may modulate the GPR18 receptor on 
macrophages. However, the robust and persistent calcium signaling induced by LPI and the 
strong suppression by 2-AG indicated complex effects at multiple cannabinoid receptors 
including GPR55 that regulate macrophage calcium signaling.  Overall, our findings support the 
hypothesis that CBD has neuroprotective potential for AD patients through both the suppression 
of inflammation and the stabilization of network activity. The precise mechanisms underlying 
these effects are not clear but cannabinoid-like receptors, such as GPR18 and GPR55, appear 
to play a significant role.  Further research on the mechanisms by which CBD controls 
inflammation and network activity have the potential to reveal novel therapies that suppress 
pathogenesis in the early stages of Alzheimer’s disease.  
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